Literature DB >> 27614750

Association of p53 codon 72 polymorphism and survival of North Indian lung cancer patients treated with platinum-based chemotherapy.

Ankita Kumari1, Charu Bahl1, Navneet Singh2, Digambar Behera2, Siddharth Sharma3.   

Abstract

p53 helps in maintaining genomic stability by undergoing cellular arrest, DNA repair or cellular apoptosis during DNA damage. So, as to find the association of p53Arg 72 Pro towards lung carcinogenesis and overall survival of North Indian lung cancer patients, single nucleotide polymorphic variant (rs1042522) was analyzed. 840 subjects including 420 cases and 420 controls were recruited and genotyped using PCR-RFLP technique for p53Arg 72 Pro polymorphic site. Association was analyzed using adjusted odds ratio along with its confidence intervals (95 % CI) and p value predicted from logistic regression whereas overall survival for lung cancer patients was obtained using Kaplan-Meir and Cox regression model for different parameters to obtain hazard ratio and survival time with statistical significance (log-rank p value). None of the variant genotypes for p53Arg 72 Pro showed any association towards lung cancer risk or any specific histological subtype. Lung cancer subjects with Pro/Pro genotype had better median survival time as compared to Arg/Pro genotype (10 months; HR = 0.65; 95 % CI = 0.45-0.95; p = 0.03). Furthermore, female lung cancer patients with Arg/Pro (HR = 0.08; 95 % CI = 0.02-0.34; p = 0.0005) and Pro/Pro (HR = 0.21; 95 % CI = 0.06-0.67; p = 0.008) genotypes showed a better overall survival and hence a better prognosis as compared to males. Our data also reveals that lung cancer patients with ECOG scores between 0 and 1 and carrying the Pro/Pro had better chances of survival. p53 codon 72 polymorphism could play a role as a prognostic marker in lung cancer patients.

Entities:  

Keywords:  Genotype; Lung cancer; Polymorphisms; Survival; p53 codon 72

Mesh:

Substances:

Year:  2016        PMID: 27614750     DOI: 10.1007/s11033-016-4072-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  49 in total

1.  Comparison of p53 mutations induced by PAH o-quinones with those caused by anti-benzo[a]pyrene diol epoxide in vitro: role of reactive oxygen and biological selection.

Authors:  Yu-Min Shen; Andrea B Troxel; Srilakshmi Vedantam; Trevor M Penning; Jeffrey Field
Journal:  Chem Res Toxicol       Date:  2006-11       Impact factor: 3.739

2.  Association study of TP53 polymorphisms with lung cancer in a Korean population.

Authors:  Hae-Yun Jung; Young Mi Whang; Jae Sook Sung; Hyoung Doo Shin; Byung Lae Park; Jun Suk Kim; Sang Won Shin; Hee Yun Seo; Jae Hong Seo; Yeul Hong Kim
Journal:  J Hum Genet       Date:  2008-03-25       Impact factor: 3.172

3.  Lack of influence of TP53 Arg72Pro and 16bp duplication polymorphisms on risk of breast cancer in Iran.

Authors:  Sahar Gohari-Lasaki; Jalal Gharesouran; Morteza Ghojazadeh; Vahid Montazeri; Seiied Moitaba Mohaddes Ardebili
Journal:  Asian Pac J Cancer Prev       Date:  2015

4.  Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility.

Authors:  J To-Figueras; M Gene; J Gomez-Catalan; C Galan; J Firvida; M Fuentes; M Rodamilans; E Huguet; J Estape; J Corbella
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-05       Impact factor: 4.254

5.  Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients.

Authors:  Athena Matakidou; Rachid El Galta; Emily L Webb; Matthew F Rudd; Helen Bridle; Tim Eisen; Richard S Houlston
Journal:  Lung Cancer       Date:  2007-04-02       Impact factor: 5.705

6.  Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk.

Authors:  Tokuki Sakiyama; Takashi Kohno; Sachiyo Mimaki; Tsutomu Ohta; Noriko Yanagitani; Tomotaka Sobue; Hideo Kunitoh; Ryusei Saito; Kimiko Shimizu; Chie Hirama; Junko Kimura; Go Maeno; Hiroshi Hirose; Takashi Eguchi; Daizo Saito; Misao Ohki; Jun Yokota
Journal:  Int J Cancer       Date:  2005-05-01       Impact factor: 7.396

Review 7.  Lung cancer in India.

Authors:  D Behera; T Balamugesh
Journal:  Indian J Chest Dis Allied Sci       Date:  2004 Oct-Dec

8.  Polymorphism Arg72Pro of p53 confers susceptibility to squamous cell carcinoma of lungs in a North Indian population.

Authors:  Anup R Tilak; Sachin Kumar; Mohan C Pant; Neeraj Mathur; Ashwani Kumar
Journal:  DNA Cell Biol       Date:  2013-01-14       Impact factor: 3.311

9.  Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer.

Authors:  T Mitsudomi; T Oyama; T Kusano; T Osaki; R Nakanishi; T Shirakusa
Journal:  J Natl Cancer Inst       Date:  1993-12-15       Impact factor: 13.506

10.  P53 codon 72 Arg/Pro polymorphism and lung cancer risk in Asians: an updated meta-analysis.

Authors:  Siyang Wang; Xingang Lan; Sheng Tan; Siwen Wang; Yu Li
Journal:  Tumour Biol       Date:  2013-06-28
View more
  3 in total

1.  Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer.

Authors:  Jelena Spasic; Milena Cavic; Nemanja Stanic; Bojan Zaric; Tomi Kovacevic; Davorin Radosavljevic; Ljudmila Nagorni-Obradovic
Journal:  Dose Response       Date:  2022-06-28       Impact factor: 2.623

2.  TP53 codon 72 Polymorphism and bladder cancer risk: a meta-analysis and emphasis on the role of tumor or smoking status.

Authors:  Lei Zhang; Yi Wang; Zhiqiang Qin; Ran Li; Rong Cong; Chengjian Ji; Xianghu Meng; Yamin Wang; Jiadong Xia; Ninghong Song
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

3.  Association between tobacco substance usage and a missense mutation in the tumor suppressor gene P53 in the Saudi Arabian population.

Authors:  Mikhlid H Almutairi; Bader O Almutairi; Turki M Alrubie; Sultan N Alharbi; Narasimha R Parine; Abdulwahed F Alrefaei; Ibrahim Aldeailej; Abdullah Alamri; Abdelhabib Semlali
Journal:  PLoS One       Date:  2021-01-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.